Journal
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 22, Issue 3, Pages -Publisher
MDPI
DOI: 10.3390/ijms22031047
Keywords
endocannabinoids; fatty acid amide hydrolase; major depressive disorder; animal models of depression
Funding
- Ontario Graduate Scholarship
- Institute of Medical Science, University of Toronto
- Canadian Institutes of Health Research Project Grant
Ask authors/readers for more resources
Studies have shown that increased FAAH expression is significantly correlated with depressive-like behaviors in animal models, and genetic knockout or pharmacological inhibition of FAAH can effectively reduce these behaviors in a dose-dependent manner. Differences in FAAH expression in depressive-like phenotypes are mainly localized in the animal prefrontal cortex, hippocampus, and striatum. Based on this, FAAH is considered a promising target for developing new pharmacotherapies for Major Depressive Disorder (MDD).
Altered activity of fatty acid amide hydrolase (FAAH), an enzyme of the endocannabinoid system, has been implicated in several neuropsychiatric disorders, including major depressive disorder (MDD). It is speculated that increased brain FAAH expression is correlated with increased depressive symptoms. The aim of this scoping review was to establish the role of FAAH expression in animal models of depression to determine the translational potential of targeting FAAH in clinical studies. A literature search employing multiple databases was performed; all original articles that assessed FAAH expression in animal models of depression were considered. Of the 216 articles that were screened for eligibility, 24 articles met inclusion criteria and were included in this review. Three key findings emerged: (1) FAAH expression is significantly increased in depressive-like phenotypes; (2) genetic knockout or pharmacological inhibition of FAAH effectively reduces depressive-like behavior, with a dose-dependent effect; and (3) differences in FAAH expression in depressive-like phenotypes were largely localized to animal prefrontal cortex, hippocampus and striatum. We conclude, based on the animal literature, that a positive relationship can be established between brain FAAH level and expression of depressive symptoms. In summary, we suggest that FAAH is a tractable target for developing novel pharmacotherapies for MDD.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available